The American Journal of Medicine
Volume 113, Issue 3 , Pages 229-232, 15 August 2002

Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection☆

  • Leslie A Lenert, MD, MS

      Affiliations

    • Department of Medicine (LAL, DL), University of California, San Diego, La Jolla, California, USA
    • Veterans Medical Research Foundation (LAL, MF, AS), San Diego, California, USA
    • Section of Health Services Research (LAL), Veterans Administration Healthcare System, San Diego, California, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Leslie A. Lenert, MD, Health Services Research and Development MC 111N1, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, California 92161, USA
    • ,
  • Martin Feddersen

      Affiliations

    • Veterans Medical Research Foundation (LAL, MF, AS), San Diego, California, USA
    • ,
  • Ann Sturley, DrPH

      Affiliations

    • Veterans Medical Research Foundation (LAL, MF, AS), San Diego, California, USA
    • ,
  • Daniel Lee, MD

      Affiliations

    • Department of Medicine (LAL, DL), University of California, San Diego, La Jolla, California, USA

Received 31 July 2001; received in revised form 21 March 2002; accepted 9 April 2002.

Keywords:  Human immunodeficiency virus infection, Lipodystrophy, Quality of life, Cost-effectiveness analysis, Computers, Anti-retroviral therapy/adverse effects

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This study was funded by a grant from GlaxoSmithKline Pharmaceuticals, Brentfort, Middlesex, United Kingdom.

PII: S0002-9343(02)01156-7

The American Journal of Medicine
Volume 113, Issue 3 , Pages 229-232, 15 August 2002

Article Tools

* Image Usage & Resolution